Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students

Namrata Banga, Paula Guss, Amit Banga, Kenneth D. Rosenman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: This study sought to determine the proportion of subjects with inadequate antibody titers at two years after pre-exposure rabies vaccination and identify variables associated with inadequate antibody titers. Methods: A retrospective chart review of vaccination records of veterinary students in Michigan, 2004-2009, was conducted. Antibody titers <0.5. IU/ml as estimated by rapid fluorescent focus inhibition test were classified as inadequate. Variables were compared between the two groups to identify factors associated with inadequate titers at two years. Results: A total of 603 subjects (mean age 24.1. ±. 4.2 years, male:female 106:497) were included. Nearly one third (177/603, 29.4%) had inadequate titers at two years. Male gender (adjusted odds ratio (AOR) 1.87, 1.07-3.27; p= 0.029), vaccine manufacturer (AOR 1.49, 1.16-1.92; p= 0.002), BMI >25 (AOR 1.61, 1.02-2.54; p= 0.043), and duration between first and third doses of vaccine >21 days (AOR 2.49, 1.26-4.97; p= 0.009) were independently associated with inadequate titers. Conclusions: Twenty-nine percent of subjects had inadequate antibody titers against rabies at 2 years. Gender, vaccine type/manufacturer, BMI of 25 or greater, and more than 21 days between the first and third doses of vaccine were independently associated with inadequate antibody titers at two years. Our data would support modifying the recommendations, so the third dose is recommended at 21 days rather than 21-28 days.

Original languageEnglish (US)
Pages (from-to)979-983
Number of pages5
JournalVaccine
Volume32
Issue number8
DOIs
StatePublished - Feb 12 2014

Fingerprint

Rabies
rabies
Medical Students
students
Vaccination
vaccination
incidence
antibodies
Antibodies
Incidence
Vaccines
vaccines
dosage
veterinarians
Students
duration
gender

Keywords

  • Antibody titers
  • Pre-exposure prophylaxis
  • Rabies vaccination
  • RFFIT

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. / Banga, Namrata; Guss, Paula; Banga, Amit; Rosenman, Kenneth D.

In: Vaccine, Vol. 32, No. 8, 12.02.2014, p. 979-983.

Research output: Contribution to journalArticle

@article{8f0e8177e0ef44558f0c28417ec69293,
title = "Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students",
abstract = "Background: This study sought to determine the proportion of subjects with inadequate antibody titers at two years after pre-exposure rabies vaccination and identify variables associated with inadequate antibody titers. Methods: A retrospective chart review of vaccination records of veterinary students in Michigan, 2004-2009, was conducted. Antibody titers <0.5. IU/ml as estimated by rapid fluorescent focus inhibition test were classified as inadequate. Variables were compared between the two groups to identify factors associated with inadequate titers at two years. Results: A total of 603 subjects (mean age 24.1. ±. 4.2 years, male:female 106:497) were included. Nearly one third (177/603, 29.4{\%}) had inadequate titers at two years. Male gender (adjusted odds ratio (AOR) 1.87, 1.07-3.27; p= 0.029), vaccine manufacturer (AOR 1.49, 1.16-1.92; p= 0.002), BMI >25 (AOR 1.61, 1.02-2.54; p= 0.043), and duration between first and third doses of vaccine >21 days (AOR 2.49, 1.26-4.97; p= 0.009) were independently associated with inadequate titers. Conclusions: Twenty-nine percent of subjects had inadequate antibody titers against rabies at 2 years. Gender, vaccine type/manufacturer, BMI of 25 or greater, and more than 21 days between the first and third doses of vaccine were independently associated with inadequate antibody titers at two years. Our data would support modifying the recommendations, so the third dose is recommended at 21 days rather than 21-28 days.",
keywords = "Antibody titers, Pre-exposure prophylaxis, Rabies vaccination, RFFIT",
author = "Namrata Banga and Paula Guss and Amit Banga and Rosenman, {Kenneth D.}",
year = "2014",
month = "2",
day = "12",
doi = "10.1016/j.vaccine.2013.12.019",
language = "English (US)",
volume = "32",
pages = "979--983",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students

AU - Banga, Namrata

AU - Guss, Paula

AU - Banga, Amit

AU - Rosenman, Kenneth D.

PY - 2014/2/12

Y1 - 2014/2/12

N2 - Background: This study sought to determine the proportion of subjects with inadequate antibody titers at two years after pre-exposure rabies vaccination and identify variables associated with inadequate antibody titers. Methods: A retrospective chart review of vaccination records of veterinary students in Michigan, 2004-2009, was conducted. Antibody titers <0.5. IU/ml as estimated by rapid fluorescent focus inhibition test were classified as inadequate. Variables were compared between the two groups to identify factors associated with inadequate titers at two years. Results: A total of 603 subjects (mean age 24.1. ±. 4.2 years, male:female 106:497) were included. Nearly one third (177/603, 29.4%) had inadequate titers at two years. Male gender (adjusted odds ratio (AOR) 1.87, 1.07-3.27; p= 0.029), vaccine manufacturer (AOR 1.49, 1.16-1.92; p= 0.002), BMI >25 (AOR 1.61, 1.02-2.54; p= 0.043), and duration between first and third doses of vaccine >21 days (AOR 2.49, 1.26-4.97; p= 0.009) were independently associated with inadequate titers. Conclusions: Twenty-nine percent of subjects had inadequate antibody titers against rabies at 2 years. Gender, vaccine type/manufacturer, BMI of 25 or greater, and more than 21 days between the first and third doses of vaccine were independently associated with inadequate antibody titers at two years. Our data would support modifying the recommendations, so the third dose is recommended at 21 days rather than 21-28 days.

AB - Background: This study sought to determine the proportion of subjects with inadequate antibody titers at two years after pre-exposure rabies vaccination and identify variables associated with inadequate antibody titers. Methods: A retrospective chart review of vaccination records of veterinary students in Michigan, 2004-2009, was conducted. Antibody titers <0.5. IU/ml as estimated by rapid fluorescent focus inhibition test were classified as inadequate. Variables were compared between the two groups to identify factors associated with inadequate titers at two years. Results: A total of 603 subjects (mean age 24.1. ±. 4.2 years, male:female 106:497) were included. Nearly one third (177/603, 29.4%) had inadequate titers at two years. Male gender (adjusted odds ratio (AOR) 1.87, 1.07-3.27; p= 0.029), vaccine manufacturer (AOR 1.49, 1.16-1.92; p= 0.002), BMI >25 (AOR 1.61, 1.02-2.54; p= 0.043), and duration between first and third doses of vaccine >21 days (AOR 2.49, 1.26-4.97; p= 0.009) were independently associated with inadequate titers. Conclusions: Twenty-nine percent of subjects had inadequate antibody titers against rabies at 2 years. Gender, vaccine type/manufacturer, BMI of 25 or greater, and more than 21 days between the first and third doses of vaccine were independently associated with inadequate antibody titers at two years. Our data would support modifying the recommendations, so the third dose is recommended at 21 days rather than 21-28 days.

KW - Antibody titers

KW - Pre-exposure prophylaxis

KW - Rabies vaccination

KW - RFFIT

UR - http://www.scopus.com/inward/record.url?scp=84892952194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892952194&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.12.019

DO - 10.1016/j.vaccine.2013.12.019

M3 - Article

C2 - 24394442

AN - SCOPUS:84892952194

VL - 32

SP - 979

EP - 983

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 8

ER -